Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- The U.K. drug regulator has approved an antibody cocktail developed by Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Roche Holding AG (OTC:RHHBY) to prevent and treat COVID-19.
- The U.K. chief medical officers confirmed the antibody would be rolled out on the National Health Service in the coming weeks.
- The Medicines and Healthcare products Regulatory Agency (MHRA) said clinical trial data shows the drug Ronapreve could help prevent infection, help resolve symptoms of severe COVID-19 infection and reduce the chances of hospitalization.
- Ronapreve, known as REGEN-COV in the U.S., can be taken via injection or infusion. It binds tightly to the coronavirus at the lining of the respiratory system and prevents it from gaining access to cells of the respiratory system, the MHRA said.
- Related: Roche's Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage.
- Earlier this month, the FDA approved the antibody cocktail for COVID-19 post-exposure prophylaxis.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: REGN shares traded higher 1.18% at $663.36 on the last check Friday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!